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A Haplotype Implicated in Schizophrenia Susceptibility Is Associated
with Reduced COMT Expression in Human Brain
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Michael J. Owen, and Michael C. O’Donovan
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The gene encoding catechol-O-methyltransferase (COMT) is a strong candidate for schizophrenia susceptibility,
owing to the role of COMT in dopamine metabolism, and the location of the gene within the deleted region in
velocardiofacial syndrome, a disorder associated with high rates of schizophrenia. Recently, a highly signiﬁcant
association was reported between schizophrenia and a COMT haplotype in a large case-control sample (Shifman
et al. 2002). In addition to a functional valinermethionine (Val/Met) polymorphism, this haplotype included two
noncoding single-nucleotide polymorphisms (SNPs) at either end of the COMT gene. Given the role of COMT in
dopamine catabolism and that deletion of 22q11 (containing COMT) is associated with schizophrenia,we postulated
that the susceptibility COMT haplotype is associated with low COMT expression. To test this hypothesis, we have
applied quantitative measures of allele-speciﬁc expression using mRNA from human brain. We demonstrate that
COMT is subject to allelic differences in expression in human brain and that the COMT haplotype implicated in
schizophrenia (Shifman et al. 2002) is associated with lower expression of COMT mRNA. We also show that the
3′ ﬂanking region SNP that gave greatest evidence for association with schizophrenia in that study is transcribed
in human brain and exhibits signiﬁcant differences in allelic expression, with lower relative expression of the associated
allele. Our results indicate that COMT variants other than the Val/Met change are of functional importance in human
brain and that the haplotype implicated in schizophrenia susceptibility is likely to exert its effect, directly or indirectly,
by down-regulating COMT expression.
Introduction
Schizophrenia (MIM 181500) is a common yet severe
psychiatric condition, characterized by profound distur-
bances of cognition, emotion, and social functioning.
Despite evidence for a substantial heritable component
(Owen et al. 2002), the genetic loci that contribute
to the disorder remain to be elucidated, and the under-
lying neurobiological mechanisms are largely unknown.
Recently, a highly signiﬁcant association was reported
between variants within the gene encoding catechol-O-
methyltransferase (COMT [MIM 116790]) and schizo-
phrenia in a large Israeli sample (Shifman et al. 2002).
The COMT gene is a strong candidate for schizophrenia
susceptibility, owing to the role of the encoded enzyme
in the metabolism of released dopamine (Axelrod and
Tomchick 1958), and its physical localization to chro-
mosome 22q11 (Grossman et al. 1992). Hyperdopami-
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nergic function has long been postulated in schizophre-
nia (van Rossum 1966; Carlsson 1978), although direct
evidence for a primary dopaminergic abnormality has
proved difﬁcult to substantiate. Chromosome 22q11
has been implicated in linkage studies of schizophrenia
(Pulver 2000) and is the site of microdeletions that are
associated with velocardiofacial syndrome (VCFS [MIM
192430]), a condition in which high rates of schizo-
phrenia have been reported (Murphy et al. 1999).
The COMT protein occurs as two distinct forms: a
soluble form found in the cell cytoplasm (S-COMT) and
a longer, membrane-bound form (MB-COMT). In most
assayed tissues, the S-COMT form predominates, ac-
counting for ∼95% of total COMT activity (Jeffery and
Roth 1984; Grossman et al. 1985). However, the MB-
COMT form is the more prevalent species in brain (Ten-
hunen et al. 1994). Studies prior to that of Shifman et
al. (2002) that investigated genetic association between
schizophrenia and the COMT gene have yielded incon-
sistent results. These have largely focused on an SNP that
produces a valinermethionine (Val/Met) substitution at
codons 108 and 158 in the S-COMT and MB-COMT
transcripts, respectively (Lachman et al. 1996). The Val/
Met polymorphism is reported to have a functional ef-
fect on enzyme activity, which is associated with altered
thermostability of the COMT protein (Lotta et al. 1995;
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Lachman et al. 1996). Although the majority of case-
control studies have failed to ﬁnd evidence for associa-
tion between this polymorphism and schizophrenia
(e.g., Daniels et al. 1996; Liou et al. 2001; but see
Ohmori et al. [1998]), preferential transmission of the
reportedly high activity (Val) allele has been reported
in several studies in which the transmission/disequilib-
rium test (TDT) was employed (e.g., Li et al. 1996;
Kunugi et al. 1997; Egan et al. 2001).
The study of Shifman et al. (2002) is the largest case-
control analysis in schizophrenia that has been reported
to date, with 1700 patients and 4,000 control subjects.
The authors tested not only the Val/Met polymorphism,
but also several other SNPs across the COMT gene. It
is interesting that the evidence for association between
schizophrenia and the Val/Met polymorphismwasmod-
est, but, when it was analyzed as part of a haplotype that
included two other noncoding SNPs, extremely high lev-
els of statistical signiﬁcance were achieved. Moreover,
the two additional polymorphisms included in the hap-
lotype—one in the ﬁrst intron of the MB-COMT tran-
script (rs737865) and one purported to lie near the 3′
UTR (rs165599)—were themselves highly signiﬁcantly
associated. These data suggest that if the COMT locus
is indeed involved in susceptibility to schizophrenia, this
cannot be wholly accounted for by the Val/Met poly-
morphism; therefore, other functional variants are likely
to exist.
One possibility is that there exists genetic variation at
the COMT locus that affects expression of the gene.
Given that COMT degrades dopamine, that most treat-
ments for schizophrenia block dopaminergic transmis-
sion (whereas drugs that enhance it are psychotomi-
metic), and that deletion of 22q11 (including COMT)
is associated with schizophrenia, we postulated that the
COMT haplotype associated with schizophrenia would
also be associated with low COMT expression.
To investigate potential cis-acting inﬂuences on gene
expression, it is possible to use SNPs within an expressed
sequence as a tag for mRNA transcribed from each chro-
mosomal allele. It is then possible to apply quantitative
methods of allele discrimination to mRNA from indi-
vidual subjects who are heterozygous for the marker
polymorphism to measure relative allelic expression
(e.g., Singer-Sam et al. 1992; Cowles et al. 2002; Yan
et al. 2002). Each allele serves as an internal control
against which expression of the other allele can be
measured within each individual mRNA sample,
thereby enabling detection of genuine cis-acting phe-
nomena that affect expression, while controlling for
trans-acting confounders.
We have applied this principle to investigate possible
cis-acting mechanisms that affect expression of the
COMT gene in human brain. In particular, we sought
to test whether the haplotype previously implicated in
schizophrenia susceptibility (Shifman et al. 2002) is also
associated with altered COMT expression. To this end,
we have assayed mRNA derived from human cerebral
cortex using a highly quantitative method of allele
discrimination (Norton et al. 2002), capable of deter-




Postmortem brain tissue derived from frontal, parie-
tal, or temporal cortex of 60 unrelated, anonymous hu-
man adults was obtained from three sources (The MRC
London Neurodegenerative Diseases Brain Bank, United
Kingdom; The Stanley Medical Research Institute Brain
Bank, Bethesda; The Karolinska Institute, Stockholm).
Subjects were drawn principally from psychiatric control
groups. From each individual, ∼500 mg of tissue was
processed for genomic DNA, by use of standard phenol/
chloroform procedures, and ∼300–500 mg of tissue was
processed for total RNA, by use of the RNAwiz isolation
reagent (Ambion). Total RNA was treated with DNAse
prior to reverse transcription, which was performed by
use of the RETROscript kit (Ambion).
Genotyping
Primers (sequences available on request) were designed
by use of the Primer3 program. PCR was performed in
a total reaction volume of 12 ml that contained 24-ng
genomic DNA template, 1# PCR buffer, dNTPs at 0.1
mM, primers at 0.12–0.24 mM, and 0.3-U “Hot Star”
Taq polymerase (Qiagen). Genotyping was performed by
use of primer extension and the SNaPshot Multiplex Kit
(Applied Biosystems).
Allele Expression Assay
GenomicDNA from all subjects was initially genotyped
to identify heterozygotes for the marker polymorphisms.
The corresponding cDNA samples were initially assayed
twice as two separate RT reactions alongside the corre-
sponding genomic DNA samples. This analysis was al-
ways replicated on a second occasion. Where the strati-
ﬁed analyses were signiﬁcant in each of the above two
experiments, a third analysis was performed that con-
tained two separate RT reactions for each individual,
each ampliﬁed twice, alongside a genomic control group.
For simplicity, the data presented below represent the
average for all assays. For assays using SNPs rs4633 and
rs165599, samples were ampliﬁed by use of primers that
were based on single exonic sequence, capable of am-
plifying either cDNA or genomic DNA. RNA samples
did not yield detectable levels of product in the absence
of an RT step. The same analytic conditions were used
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for genomic DNA and cDNA for these principal analyses
to enable us to use the average of the ratios observed
from genomic DNA (as a perfect 1:1 ratio of the two
alleles) to correct allelic ratios obtained from cDNA
analyses for any inequalities in allelic representation spe-
ciﬁc to each assay (Hoogendoorn et al. 2000). Since we
have previously shown that allelic representation in in-
dividual samples can be inﬂuenced by polymorphisms
under the primers (unpublished data), prior to applying
the general correction factor to the cDNA, we ensured
that the relative allelic representations in all genomic
samples were equivalent. Because rs165688 (encoding
108/158 Val/Met) is too near an intron-exon boundary
to allow the design of common genomic and cDNA
primers, it was genotyped from genomic DNA by use
of primers that were based on adjacent intronic se-
quence, whereas cDNA was assayed at this SNP by
use of “cDNA-speciﬁc” primers that spanned intron-
exon boundaries.
Allelic representation was measured by use of primer
extension and SNaPshot chemistry (Applied Biosystems).
Ampliﬁed samples were incubated with 1 U shrimp al-
kaline phosphatase (Amersham) and 2 U exonuclease I
(Amersham) for 45 min at 37C and, then, for 15 min
at 85C, prior to primer extension. Primer extension re-
actions were performed in a total volume of 10 ml, which
contained 2 ml treated PCR product, 4.5 ml SNaPshot
kit, 2.5 ml water, and 0.3–0.5 pMol extension primer.
Primer extension thermocycling conditions consisted of
an initial step of 95C for 2 min, followed by 25 cycles
of 95C for 5 s, 43C for 5 s, and 60C for 5 s. Following
primer extension, reaction products were treated with
0.5 U shrimp alkaline phosphatase (Amersham) for 45
min at 37C and, then, for 15 min at 85C. Aliquots of
1 ml SNaPshot reaction product were combined with 9
ml Hi-Di formamide and loaded onto a 3100 DNA se-
quencer (Applied Biosystems). Products were electropho-
resed on a 36-cm capillary array at 60C and data pro-
cessed by use of Genescan Analysis version 3.7 software
(Applied Biosystems). Peak heights of allele-speciﬁc ex-
tended primers were determined by use of Genotyper
version 2.5 software (Applied Biosystems). The ratio of
cDNA peak heights, corrected, where possible, by use
of the average genomic ratio from all heterozygous sam-
ples, was used to calculate relative expression of the two
alleles in each individual sample.
Statistical Analysis
Predicted haplotype frequencies were calculated by use
of EH plus (Zhao et al. 2000). D′ and r2 measures of
linkage disequilibrium (LD) were calculated by use of
the program ldmax within the GOLD software package.
Group comparisons were analyzed by t test (two tailed)
or, where there was more than one group, by one-way
ANOVA, by use ofMinitab Statistical Software (Minitab
release 13.32).
Results
Genotyping for COMT Polymorphisms
The sample was individually genotyped for SNPs
rs737865 and rs165599 (which gave strongest evidence
for association in the study of Shifman et al. [2002]),
rs165688 (which encoded the Val/Met polymorphism),
and rs4633 (a synonymous SNP located within exon 3
of theMB-COMT transcript and exon 1 of the S-COMT
transcript). Positions of SNPs and predicted haplotype
frequencies are shown in ﬁgure 1. Consistent with pre-
vious data (Shifman et al. 2002), SNPs rs165688 (Val/
Met) and rs4633 were found to be in complete LD
( ; ). SNP rs737865, located within intron′ 2D p 1 r p 1
1 of the MB-COMT transcript, also showed strong LD
with SNPs rs165688/rs4633 ( ; ).′ 2D p 0.84 r p 0.24
SNP rs165599, located at the 3′ end of the COMT gene,
showed more modest LD with rs165688/rs4633 ( ′D p
; ).20.46 r p 0.12
Cis-Acting Differences in COMT Expression
Alleles are not equally represented by the SNaPshot
assay, even when present in equimolar concentrations.
Therefore, to obtain exact estimates of the relative allelic
expression, it is necessary to correct the estimate obtained
from cDNA for differential representation of alleles with
a correction factor derived from genomic DNA, where
the exact ratio of alleles is known to be equimolar. SNP
rs165688 (Val/Met) is too near an intron/exon boundary
to enable the design of primers that amplify both genomic
DNA and cDNA. Our primary analysis was, therefore,
based on expressed SNP rs4633, which is in perfect LD
with the Val/Met polymorphism. Twenty-three hetero-
zygotes were assayed for allelic differences in expression
at SNP rs4633 (ﬁg. 2). The genomic ratios for each in-
dividual sample were similar, which indicates that the data
are not confounded by unidentiﬁed sequence variants that
might alter the relative efﬁciencies of allelic representa-
tion between samples (on the basis of two measures from
each genomic sample, the maximum deviation from the
mean ratio was 6%). The correction factor for ine-
qualities in allelic representation was, therefore, derived
from the average genomic ratio obtained from all het-
erozygotes in each experiment. Analysis of the corrected
cDNA peak-height ratios in all three replicate analyses
showed that, in all individuals, the C allele was signif-
icantly reduced in expression, relative to the T allele.
Even though they were conducted on three different oc-
casions, repeat assays showed good reproducibility of
individual cDNA allelic ratios, with an average SD of
0.03. When the data from all individuals across all ex-
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Figure 1 Genomic structure of the COMT gene, which indicates exon usage of the membrane-bound (MB-COMT) and soluble (S-COMT)
forms. Location of assayed SNPs are shown, together with estimated haplotype frequencies.
periments were combined, the expression of the C allele
remained signiﬁcantly reduced ( ), with an av-P ! .0001
erage relative reduction of 17% (95% CI 14%–21%).
The C allele at rs4633 always lies on the same haplotype
as the G allele at rs165688 (encoding valine), which
indicates that the valine transcripts are expressed at a
slightly lower level than those encoding the 108/158 me-
thionine allele in human brain. In accordance, when SNP
rs165688 was used to assay the same mRNA samples,
the relative allelic differences in expression correlated
signiﬁcantly with those obtained when assayed using
SNP rs4633 (correlation 0.7; ), despite the rel-P ! .001
atively limited range of ratios observed in each assay.
The strongest evidence for association with schizo-
phrenia in the study of Shifman et al. (2002) was yielded
by a three-marker haplotype that consisted of a variant
in intron 1 of the MB-COMT transcript (rs737865),
a polymorphism at the 3′ end of the gene (rs165599), and
the valine-encoding allele of the Val108/158Met poly-
morphism (ﬁg. 1). If reduced expression of COMT is
responsible for this association, we would expect the
risk haplotype to be the lowest expressed haplotype. We
therefore predict that individuals who carry one copy of
the risk haplotype and one copy of a nonrisk haplotype
will display greater differences in the relative expression
of their haplotypes than individuals who carry two copies
of nonrisk haplotypes. To test this, the rs4633 data were
stratiﬁed according to whether subjects carried either
zero or one copy of the risk haplotype, as deﬁned by
rs4633 and the speciﬁc loci included in the stratiﬁed
analyses (table 1). However, we added an extra level
of stringency to our analysis because Shifman and col-
leagues (2002) also postulate that their data represent
the presence of independent risk alleles at these loci. We
therefore required that the subjects we examined with
one copy of the risk haplotype not carry any of the risk
alleles on the other haplotype; that is, they were hetero-
zygous at the particular loci included in each stratiﬁed
analysis. Conversely, all subjects without a risk haplo-
type were required to be homozygous at each of the loci
included in the stratiﬁed analysis, other than the rs16588
polymorphism (owing to the complete LD between it
and the test locus), thereby achieving internal control
for any inﬂuence these loci might have on expression.
Although these stratiﬁed analyses included subjects who
were homozygous at some of the loci, we re-emphasize
that all subjects were heterozygous at the test locus and,
therefore, each observation is still controlled for the
trans-acting and tissue-speciﬁc variables that could con-
found such comparisons when based on measurement
of the total mRNA level.
Despite small samples sizes, subjects who were het-
erozygous for SNP rs737865 ( ) showed a sig-np 11
niﬁcant reduction, in all three experiments (overall
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Figure 2 Comparison between observed genomic ratios and corrected cDNA ratios assayed at SNP rs4633 ( ). Data are expressednp 23
as ratio of C:T alleles. The data for genomic DNA are the averages of two measurements for each individual sample. The data for cDNA are
the averages of eight estimates for each individual sample.
), in the expression of the C allele at rs4633Pp .003
compared with rs737865 homozygotes ( ). Thenp 11
haplotype phases are unambiguous with respect to the
rs737865 homozygotes but not the rs737865/rs4633
double heterozygotes. However, given the observed
haplotype frequencies, the probability is 0.93 that the
haplotypes constructed from rs737865 and the Val/
Met polymorphism in a double heterozygote are C-G
and T-A. Using the nomenclature of Shifman et al.
(2002), this corresponds to the G-G and A-A haplo-
types that, in that study, were respectively over- and
underrepresented in schizophrenia.
When the same procedure was applied to hetero-
zygosity ( ) and homozygosity ( ) at SNPnp 13 np 7
rs165599, there was only a nonsigniﬁcant trend toward
lower C-allele expression at rs4633 ( ). For thisPp .22
analysis, the probability was 0.83 that the haplotypes
constructed from the Val/Met and rs165599 loci in dou-
ble heterozygotes are G-G and A-A, corresponding to
the haplotypes over- and underrepresented, respectively,
in schizophrenia (Shifman et al. 2002).
The biggest reduction in expression of the C allele at
rs4633 was observed in subjects who were heterozygous
for both rs737865 and rs165599 ( ), comparedwithnp 7
those who were homozygous at both these loci ( ).np 5
In individuals who were heterozygous at both loci, the
C allele was underexpressed in all three independent ex-
periments, with an overall mean of 22%, compared with
a mean reduction of 13% in those rs4633 heterozy-
gotes who were homozygous for SNPs rs737865 and
rs165599. Despite the small sample sizes, this difference
was signiﬁcant in each individual assay and where all
data were combined ( ). The probability is 0.84Pp .023
that, in each treble heterozygote, the phase of the lowest
expression haplotype contains the C allele at rs737865
(forward sense, G, according to Shifman et al. [2002]),
the G allele at rs16588 (encoding valine), and the G allele
at rs165599. This is precisely the haplotype that was ov-
errepresented in patients with schizophrenia in the study
of Shifman et al. (2002). Very similar results were ob-
tained for identical analyses we performed without the
extra requirement of homozygosity and heterozygosity
at rs737865 and rs165599 in subjects with zero and one
risk haplotypes, respectively (data not shown).
The genetic analysis of Shifman et al. (2002) suggested
sex-speciﬁc effects of the associated alleles, both in terms
of allele frequency in the general population and in the
strength of association with schizophrenia. However, no
Bray et al.: Allelic Variation in COMT Expression 157
Table 1
Analysis of the Relative Expression of COMT Alleles, as Assayed at SNP rs4633
GENOTYPE AT LOCI
MEAN REDUCTION







( )′D p .84
rs165599
( )′D p .46
1 Heterozygous … … 17 (5) !.0001
0 Heterozygous Homozygous … 14 (4) …
1 Heterozygous Heterozygous … 20 (4) .003
0 Heterozygous … Homozygous 16 (5) …
1 Heterozygous … Heterozygous 19 (5) .22
0 Heterozygous Homozygous Homozygous 13 (5) …
1 Heterozygous Heterozygous Heterozygous 22 (4) .023
NOTE.—Subjects ﬁrst classiﬁed into those carrying no risk haplotypes and those with a high prob-
ability of carrying a single risk haplotype, as identiﬁed by Shifman and colleagues (2002). The genotype
status at the other loci are then required to be respectively homozygous and heterozygous, to exclude
confounding by independent effects of the individual risk alleles. Owing to the complete LD between
SNP rs165688 (Val/Met) and the rs4633 test locus, all samples are heterozygous at rs165688, and
there are, therefore, no individuals without the risk allele at this locus. The comparative group for this
analysis is the ratio observed in genomic DNA.
differences in allelic ratio were observed between males
( ) and females ( ) heterozygous for SNPnp 12 np 11
rs4633 ( ) or in the subset who were also hetero-Pp .74
zygous for SNP rs737865 (7M; 4F; ). Compari-Pp .74
son between rs4633 allelic ratios from cDNA derived
from frontal cortex ( ), temporal cortex ( ),np 15 np 5
and parietal cortex ( ) also showed no signiﬁcantnp 3
differences (one-way ANOVA; , ).Fp 0.89 Pp .42
SNP rs165599 Is Transcribed in Human Brain and
Shows Allelic Differences in Expression
In the study of Shifman and colleagues (2002), SNP
rs165599 was the single polymorphism that showed the
most signiﬁcant evidence for association with schizo-
phrenia. This SNP was described as being near the 3′ UTR
of COMT, rather than within it, as it is located ∼250
bp downstream from the putative polyadenylation site
(Tenhunen et al. 1994). However, certain human EST se-
quences held in the GenBank database that contain both
knownCOMT cDNA sequence and sequence containing
SNP rs165599 (e.g., GI: 24031016; GI: 16174602) sug-
gest that SNP is included in at least some COMT tran-
scripts. Using a forward primer located within known
COMT sequence and a reverse that is downstream of
SNP rs165599, we were able to amplify and sequence
this fragment from cDNA samples, thereby conﬁrming
the presence of these transcripts in human brain. Since
no product was generated from RNA samples in the
absence of reverse transcription, this could not be a result
of genomic DNA contamination.
We assayed COMT expression using SNP rs165599
itself as a copy-speciﬁc tag, using primers that are both
3′ to the original putative polyadenylation site (Tenhu-
nen et al. 1994), and therefore speciﬁc to transcripts con-
taining this polymorphism. A total of 30 individuals het-
erozygous for SNP rs165599 were assayed (ﬁg. 3). The
G allele of SNP rs165599 (the allele that is overrepre-
sented in schizophrenia in the study of Shifman et al.
[2002]) showed lower expression relative to the A allele
at this locus in all individuals (range 12%–43% relative
reduction averaged across independent experiments).
The data points from each cDNA sample showed good
reproducibility, with an average SD of 0.06. When data
from all individuals were combined, this difference in
allelic ratio was signiﬁcant in each individual experiment
and in the combined analysis ( ), with the GP ! .0001
allele showing an average relative reduction of 24%.
Unlike data obtained at SNP rs4633, stratiﬁcation by
other genotypes did not result in differences in allelic
expression at this locus (data not shown). Aswith similar
analyses of rs4633 data, no signiﬁcant difference was
observed in allelic ratio at SNP rs165599 between males
( ) and females ( ) ( ) or between thenp 20 np 10 Pp .76
three tested brain regions of frontal cortex ( ), tem-np 20
poral cortex ( ), and parietal cortex ( ) (one-np 6 np 4
way ANOVA, ; ).Fp 2.29 Pp .12
Discussion
Using a powerful method for detecting cis-acting inﬂu-
ences on gene expression (Yan et al. 2002), we have
demonstrated altered allelic expression of COMT tran-
scripts in human brain. Moreover, when we stratiﬁed the
analysis according to the other loci that Shifman and
colleagues (2002) used to convincingly implicateCOMT
in schizophrenia, we demonstrated clear evidence for
increased effects on COMT expression at the rs4633
locus, a proxy for the Val/Met polymorphism. Finally,
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Figure 3 Comparison between observed genomic ratios and corrected cDNA ratios assayed at SNP rs165599 ( ). Data are expressednp 30
as ratio of G:A alleles. The data for genomic DNA are the averages of two measurements for each individual sample. The data for cDNA are
the averages of four estimates for each individual sample.
we have shown that the single SNP giving greatest evi-
dence for association with schizophrenia in the previous
study is transcribed in human brain and exhibits signi-
ﬁcant differences in allelic expression, again with lower
relative expression of the associated allele.
Our initial analysis of allelic expressionwas performed
by use of a synonymous coding SNP that occurs in all
known COMT transcripts (rs4633). This was selected
because it is sufﬁciently distant from the intron-exon
boundaries to allow ampliﬁcation of the single exon,
with primers that could be used to amplify the equivalent
sequence from genomic DNA. The use of precisely the
same analytic conditions for cDNA and genomic DNA
is important to enable cDNA ratios to be corrected for
inequalities in allele representation (Hoogendoorn et al.
2000). The average allelic ratio derived from genomic
heterozygotes is the ideal control for such inequalities,
because it constitutes a perfect 1:1 ratio of the two
alleles. The direction and extent of any allelic variation
in expression in any individual sample can thus be cal-
culated by comparison with the derived 1:1 ratio.
The majority of studies that have sought to test ge-
netic association with the COMT gene have focused on
the nonsynonymous SNP rs165688, which produces a
valinermethionine (Val/Met) substitution in the encoded
protein. The proximity of this SNP to an intron-exon
boundary precluded the use of common genomic prim-
ers with which to correct observed cDNA ratios. How-
ever, the perfect LD between SNP rs165688 and SNP
rs4633 allows data from this alternative SNP to be used
as a proxy for the extent and direction of allelic differ-
ences in its expression. This is borne out by the signiﬁ-
cant correlation observed between cDNA ratios at each
site, despite the relatively limited range of observed ra-
tios. The present data, therefore, indicate that transcripts
that contain the G allele at SNP rs165688, encoding
108/158 valine, are expressed in human brain at a slightly
lower level than those encoding the methionine allele.
When cDNA ratios derived from analysis of rs4633
heterozygotes were stratiﬁed according to genotypes
at two other SNPs in the COMT gene (rs737865 and
rs165599) that had previously shown association with
schizophrenia (Shifman et al. 2002), signiﬁcant differ-
ences in allele ratios were observed. Despite small group
sizes, our data show that some of the variance in allelic
expression observed at rs4633/rs165688 can be ac-
counted for by genotypes at these two other loci. In
particular, we predicted that the relative differences in
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expression levels would be greatest in individuals who
carried one copy of the schizophrenia risk haplotype
that consists of the C allele at rs737865 (which corre-
sponds to the G allele in the study of Shifman et al. [2002]
forward sense), the G allele at rs165688 (encoding 108/
158 valine) and the G allele at rs165599, and one copy
of the T-A-A haplotype that was less common in schi-
zophrenics than control subjects in the study of Shifman
et al. (2002). Despite the fact that our phase allocation
was imperfect, our data are as predicted by the hy-
pothesis. Thus, the schizophrenia-risk haplotype showed
signiﬁcant underexpression in our subjects and also
showed a magnitude of underexpression that is greater
than can be attributed to the Val/Met locus alone.
The SNP that showed the strongest association with
schizophrenia in the study of Shifman et al. (2002) when
tested singularly was rs165599. Although the sequence
containing SNP rs165599 is slightly downstream of the
predicted COMT polyadenylation site (Tenhunen et al.
1994) and is absent from most (but not all) EST se-
quences in the GenBank database, we were able to am-
plify it from brain cDNA that was free from genomic
contamination, which conﬁrms that it is expressed in
human brain. It is, therefore, likely that an alterna-
tive, more 3′ polyadenylation site is utilized in some
COMT transcripts, in human brain, at least. When
SNP rs165599 was used as a tag for expression of tran-
scripts that contained this 3′ sequence, signiﬁcant dif-
ferences in allelic expression were again observed. These
differences were more pronounced than were seen for
rs4633, which suggests that it is associated with larger
changes in the transcripts that contain the longer 3′
UTR. Again, the allele at SNP rs165599 that showed
lower relative expression (the G allele) was the allele
that was overrepresented in schizophrenic patients in
the study of Shifman et al. (2002). Since the range of
relative allelic expression was observed in one direction,
with all assayed heterozygotes showing a relative re-
duction of the G allele, these data suggest that it is
either SNP rs165599 itself responsible for the observed
differences or one that is in very strong LD with it.
Although many variants may potentially result in dif-
ferential expression of a gene, it is a striking ﬁnding that
the allelic differences in COMT expression we have dem-
onstrated are associated with the particular variants and
haplotypes that others have implicated in schizophrenia.
Moreover, the direction of the effect we have seen is
consistent with predictions that arise from the increased
incidence of schizophrenia observed in VCFS (Murphy
et al. 1999), where interstitial deletions typically encom-
pass the COMT gene (Morrow et al. 1995), and with
the classic hyperdopaminergic biochemical hypothesis
of schizophrenia (van Rossum 1966; Carlsson 1978).
That is, we have shown that the implicated haplotype
is associated with reduced expression of the COMT
gene in the CNS. However, it is more difﬁcult to rec-
oncile with experiments that suggest that a structural
change brought about by the valine-encoding al-
lele—shown to be associated with lower expression in
the present analysis—is responsible for higher COMT
activity (Lotta et al. 1995; Lachman et al. 1996). One
explanation might rest on the differences between the
forms of COMT that are expressed in brain and those
tissues that have traditionally been used to assayCOMT
function, such as blood and liver. The COMT protein
occurs as two distinct forms: a soluble form found in
the cell cytoplasm (S-COMT) and a longer, membrane-
bound form (MB-COMT). Whereas, in most assayed
tissues, the S-COMT form accounts for ∼95% of total
COMT activity (Jeffery and Roth 1984; Grossman et
al. 1985), it is the MB-COMT form that is more prev-
alent in brain (Tenhunen et al. 1994). Since studies sug-
gesting functional consequences of the Val/Met poly-
morphism have focused on the S-COMT form, these
results might not be applicable to human brain. Con-
versely, lower allelic expression seen in brain might not
correlate with that seen in other tissues. For example,
the present analysis provides strong evidence for as-
sociation between lower allelic expression and an SNP
within intron 1 of MB-COMT (rs737865). It is quite
plausible that this polymorphism has no peripheral ef-
fect, since S-COMT is transcribed by use of a separate
promoter that is 5′ to exon 3 of the MB-COMT gene
(Tenhunen et al. 1994) and which is, therefore, 3′ to the
intron 1 polymorphism.
The present analysis does not address whether allelic
differences in RNA expression translate to similar dif-
ferences at the protein level. As with allelic differences
in overall COMT mRNA levels observed in this study,
these differences may well be rather small, althoughmore
pronounced differences in speciﬁc transcribed forms are
possible.
The present study employed a powerfulwithin-subjects
technique that detects cis-acting inﬂuences on gene ex-
pression, while controlling for the confounding effects
of trans-acting factors. Although this allowed us to ob-
tain strong evidence for functional inﬂuences beyond
those attributable to the Val/Met polymorphism, we can-
not distinguish formally between the variants that are
functional per se and those that are in LD with the
assayed SNPs. Thus, although our results, together with
those of Shifman et al. (2002), suggest that future ge-
netic studies that investigate association with the COMT
gene should take account of polymorphisms other than
the Val/Met polymorphism, more detailed functional
analyses of other SNPs in and around the COMT gene
will be required to identify the speciﬁc risk variants
in schizophrenia.
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